Levetiracetam (LEV) is effective in controlling focal seizures as adjunctive therapy in adults, children and in infants and as initial monotherapy in adults with newly diagnosed epilepsy. Recent data suggests that it may be effective also in idiopathic generalized epilepsy (IGE). Some antiepileptic drugs (AEDs) may a aggravate seizures in IGEs. Carbamazepine is known for this and lamotrigine has been reported to aggravate myoclonic seizure. [1] [2] [3] We report three children with newly diagnosed IGEs attending our neuropaediatric clinic that had an important increase in seizure frequency on starting treatment with LEV. This increase was seen within the first week of treatment with LEV. Seizures went into remission when LEV was switched to an alternative. We defined aggravation as an increase in seizures by more than 50% over baseline frequency on starting an AED without irregular use of the medication or concomitant inappropriate lifestyle.
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Cases
Case 1 is an 8-year-old boy, the first child of healthy, unrelated parents. Psychomotor development was normal. He was seen in clinic after two generalized tonic clonic seizures and then it became apparent that he was having early morning myoclonic seizures. Mean seizures frequency was about 10 seizures a day. Neurologic examination was normal. Brain MRI was normal. A 24 h-video EEG showed normal background and generalized polyspike-wave discharges (GPSWD) inter-ictally (Fig. 1) . Juvenile myoclonic epilepsy (JME) was diagnosed and LEV started at 250 mg/day (6 mg/kg). Seizure frequency quickly increased and exacerbated further on increasing LEV to 500 mg/day. Seizures were happening up to 20 times a day and occurring randomly. After a week on this dose he was started on sodium valproate 500 mg/day and the dose of LEV halved leading to a significant decrease in seizures. LEV was completed stopped after a week and he has been in remission for up to six month since.
Case 2 is a 10-year-old boy, the first child of healthy, unrelated parents who had normal psychomotor development. He developed myoclonic seizures on awakening four months before presentation and was having up to 7 episodes of myoclonus a day. Neurologic examination was normal as was a Brain MRI. 24 h-video EEG recording showed generalised spike-wave discharges (GSWD) and GPSWD inter-ictally (Fig. 2) . JME was diagnosed and LEV was prescribed starting at 125 mg/day (5 mg/ kg). His seizures increased and worsened further when the dose was increased to 250 mg/day. He was having over 10 seizures a day. Treatment was switched to sodium valproate and he became seizure-free.
Case 3 is also a 10-year-old boy, the first child of healthy, unrelated parents, with normal psychomotor development. He was having early morning myoclonic seizures for up to 6 months on presentation and these were happening up to 6-8 times a day. Neurologic examination and MRI brain were normal. A 24 h-video EEG showed GPSWD inter-ictally. JME was diagnosed and he was also started on LEV 250 mg/day (7 mg/kg). Seizures persisted and LEV was increased to 500 mg/day. Seizures then increased to up to 12 times a day and started to occur randomly. Treatment was switched to sodium valproate and seizures quickly remitted. When seen 6 months later, he was still completely seizure free.
Discussion
It is likely that all 3 children had JME. As typical in this syndrome, case 1 presented after having convulsions and then with Some antiepileptic drugs (AEDs) have been reported to aggravate generalized seizures. We have seen three children whose myoclonic seizures increased on starting treatment with Levetiracetam. In all seizures aggravation was temporally associated to the introduction of the drug. All became seizure-free on withdrawal of levetiracetam with a switch to an alternative antiepileptic drug and this persisted for at least 6 months. This suggests that some children with myoclonic seizures may have an aggravation on starting treatment with levetiracetam but this requires further studies.
ß 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
the benefit of hindsight was clear that he was having early morning myoclonic seizures. The remaining two presented because of early morning myoclonus. Valproate is the usual treatment for JME but there are concerns about it tolerability particularly in younger people and LEV has recently been suggested as possible alternative. 4, 5 In China, some parents are anxious about potential cognitive effects and weight gain with valproate and they prefer LEV as an initial treatment in preference to valproate when given the choice. We report the aggravation of myoclonic seizures on starting treatment with LEV in three children with likely JME. AEDs may occasionally aggravate seizures in people with IGEs such as JME. 2 A causal and temporal relationship with starting treatment with the offending drugs needs to be seen. Such a temporal relationship was clearly seen in our patients. This detrimental effect reversed with the withdrawal of LEV and initiation of treatment with valproate. There were no untoward effects in these patients probably related to the early recognition of the problem. This is important as often worsening of seizures may herald convulsions and even status epilepticus if the offending drug is not withdrawn.
LEV is the first and to date the only newer AED licensed for the treatment of myoclonic seizures. 6 It is a likely candidate to replace valproate in the treatment of JME. Our observation, may suggest that LEV, although a broad spectrum AED with an unique mechanism of action, could aggravate myoclonic seizures in some patients. It is difficult at this stage to draw conclusions on any potential underlying mechanism for this reaction. In some children with refractory epilepsy, an increase in seizure frequency was related to the initial high doses of LEV. 7 Starting dose of LEV in our 3 patients (5-7 mg/kg) was relatively low and unlikely to be responsible. Generalized seizures when aggravated are related to the mechanisms of action of the offending drug, particularly sodium channel blockers and GABA-ergic drugs. 7 As the putative mechanism of action of LEV is largely unknown it is difficult to speculate about this.
[ ( F i g . _ 1 ) T D $ F I G ] [ ( F i g . _ 2 ) T D $ F I G ] None of our patients was re-challenged with LEV, so clear causality cannot be clearly established. Nevertheless, we feel that our experience with these cases should be brought to the attention of other physicians particularly as LEV is taking place as a first line treatment for myoclonic seizures.
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